论文部分内容阅读
目的:研究丙氨瑞林治疗子宫内膜增生时对卵巢功能调节激素的影响,以及在其治疗之后卵巢功能恢复情况。方法:将子宫内膜增生患者随机分成两组:丙氨瑞林组和炔诺酮组(对照组)。采用放射免疫测定法测定两组用药前后卵泡刺激素(FSH)、黄体生成素(LH)、E2、T、P、PRL水平来评价两种药物治疗对卵巢调节激素的影响;随访药物治疗后月经恢复时间,以其作为卵巢功能恢复时间来评价两种药物治疗之后卵巢功能恢复状况。结果:(1)丙氨瑞林组用药后FSH、LH及E2均低于用药前(P<0.05);(2)炔诺酮用药后E2水平降低(P<0.05);(3)丙氨瑞林组用药后FSH、LH及T较炔诺酮组降低明显(P<0.05)。(4)丙氨瑞林组停药后卵巢功能恢复时间短于炔诺酮组(P<0.05)。结论:(1)丙氨瑞林治疗子宫内膜增生后可以降低FSH、LH及E2,而炔诺酮仅能降低E2;E2降低的水平在2组差异无统计学意义。(2)丙氨瑞林治疗组停药后卵巢功能恢复较快,优于炔诺酮组。
OBJECTIVE: To investigate the effect of avermectin on ovarian hormones in the treatment of endometrial hyperplasia, and the recovery of ovarian function after its treatment. Methods: Patients with endometrial hyperplasia were randomly divided into two groups: the arelin group and the norethisterone group (control group). The levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), E2, T, P, PRL before and after treatment were measured by radioimmunoassay to evaluate the effect of two drugs on ovarian hormones. Follow-up menstrual Recovery time was used as the recovery time of ovarian function to evaluate the recovery of ovarian function after the two drugs were treated. Results: (1) The levels of FSH, LH and E2 in the group receiving alarelin after treatment were lower than those before treatment (P <0.05); (2) The level of E2 decreased after administration of norethindrone (P <0.05) The levels of FSH, LH and T in the Ruilin group were significantly lower than those in the norethindrone group (P <0.05). (4) The ovarian function recovery time in the alarelin group was shorter than that in the norethindrone group (P <0.05). Conclusions: (1) After treatment of endometrial hyperplasia, ararelin can reduce FSH, LH and E2, while norethindrone can only reduce E2; There is no significant difference in E2 between the two groups. (2) The ovarian function recovered faster in the alarelin treatment group than in the norethisterone group.